Dr.chem. Peteris Trapencieris is the coauthor of the antiischemic drug mildronate and anticancer immunomodulator leakadine. His research work covers various fields of aliphatic and heterocyclic unnatural amino acids.Dr.chem. Peteris Trapencieris was born in Rujiena, Latvia. He is the coauthor of the antiischemic drug mildronate and anticancer immunomodulator leakadine. His research work covers various fields of aliphatic and heterocyclic unnatural amino acids, particularly the chemistry of heterocycles (aziridines, oxaziridines and indoles), steroids (estradiols and cholic acids) and azasugars (hydroxylated 1.2-oxazines and 1.2-oxazolidines). He investigates named reactions, such as the multicomponent Ugi reaction, Nenicesku reaction mechanisms, and their applications in organic chemistry, in order to increase the borders of building blocks for new drug design.
Since 1974 he has been working at the Latvian Institute of Organic Synthesis and heads the Department of Organic Chemistry since 2001. He has delivered numerous lectures abroad, and is author of 120 publications, including 60 patents.
Dr.chem Peteris Trapencieris’ interests include: asymmetric synthesis of unnatural aminoacids; synthesis and investigation of small 3- and 4-membered heterocycles; stereoselective synthesis of natural products, and the investigation of ferment and receptor binding active compounds.
He has a Bachelor degree in Chemistry which he got at the Latvian State University Chemistry Department in 1974, followed by a Dr.chem. degree at the Institute of Organic Synthesis of the Latvian Academy of Sciences in 1982, and Postdoctoral studies at the Academy of Sciences Central Institute of Organic Chemistry (1990), and the University of Wisconsin (Madison, USA, 1992-1993).